Genelux Corporation (GNLX)
(Delayed Data from NSDQ)
$3.15 USD
-0.19 (-5.69%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $3.14 -0.01 (-0.32%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
GNLX 3.15 -0.19(-5.69%)
Will GNLX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for GNLX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GNLX
Genelux Corporation (GNLX) Upgraded to Buy: Here's What You Should Know
Is EUROFINS SCIENT (ERFSF) Outperforming Other Medical Stocks This Year?
GNLX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Down -29.7% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround
Other News for GNLX
Genelux GAAP EPS of -$0.20 beats by $0.02
Genelux reports Q2 EPS (20c), consensus (22c)
Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business ...
Genelux (GNLX) Receives Buy Rating from Lucid Capital | GNLX Stock News
Genelux initiated with bullish view at Lucid Capital, here's why